Please assess the completion status of the following clinical trial:

Trial Title: Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Type 1 diabetes and end stage renal disease.~* Women of childbearing potential must have had a negative pregnancy test (serum or urine).~* Patient agrees to participate in the study and sign an informed consent.~* Patient has no known contraindication to the administration of rapamycin or mycophenolate mofetil.~* Patient has no history of hypersensitivity to rapamycin or mycophenolate mofetil.~Exclusion Criteria:~* Patient has history of a malignancy within two years, with the exception of adequately treated localized squamous or basal cell carcinoma of the skin without evidence of recurrence.~* Patient is currently abusing drugs or alcohol.~* Patient is known or suspected to have an active infection or be seropositive for hepatitis B surface antigen (HBsAg), hepatitis C (HCV) or human immunodeficiency virus (HIV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus plus MMF plus Steroids (Type: ACTIVE_COMPARATOR): Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
- Tacrolimus plus Rapamycin plus Steroids (Type: EXPERIMENTAL): Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).